Literature DB >> 15077168

Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations.

Paloma Fernandez1, Julian Carretero, Pedro P Medina, Ana I Jimenez, Sandra Rodriguez-Perales, Maria F Paz, Juan C Cigudosa, Manel Esteller, Luis Lombardia, Manuel Morente, Lydia Sanchez-Verde, Teresa Sotelo, Montserrat Sanchez-Cespedes.   

Abstract

LKB1, a tumor-suppressor gene that codifies for a serine/threonine kinase, is mutated in the germ-line of patients affected with the Peutz-Jeghers syndrome (PJS), which have an increased incidence of several cancers including gastrointestinal, pancreatic and lung carcinomas. Regarding tumors arising in non-PJS patients, we recently observed that at least one-third of lung adenocarcinomas (LADs) harbor somatic LKB1 gene mutations, supporting a role for LKB1 in the origin of some sporadic tumors. To characterize the pattern of LKB1 mutations in LADs further, we first screened for LKB1 gene alterations (gene mutations, promoter hypermethylation and homozygous deletions) in 19 LADs and, in agreement with our previous data, five of them (26%) were shown to harbor mutations, all of which gave rise to a truncated protein. Recent reports demonstrate that LKB1 is able to suppress cell growth, but little is known about the specific mechanism by which it functions. To further our understanding of LKB1 function, we analysed global expression in lung primary tumors using cDNA microarrays to identify LKB1-specific variations in gene expression. In all, 34 transcripts, 24 of which corresponded to known genes, differed significantly between tumors with and without LKB1 gene alterations. Among the most remarkable findings was deregulation of transcripts involved in signal transduction (e.g. FRAP1/mTOR, ARAF1 and ROCK2), cytoskeleton (e.g. MPP1), transcription factors (e.g. MEIS2, ATF5), metabolism of AMP (AMPD3 and APRT) and ubiquitinization (e.g. USP16 and UBE2L3). Real-time quantitative RT-PCR on 15 tumors confirmed the upregulation of the homeobox MEIS2 and of the AMP-metabolism AMPD3 transcripts in LKB1-mutant tumors. In addition, immunohistochemistry in 10 of the lung tumors showed the absence of phosphorylated FRAP1/mTOR protein in LKB1-mutant tumors, indicating that LKB1 mutations do not lead to FRAP1/mTOR protein kinase activation. In conclusion, our results reveal that several important factors contribute to LKB1-mediated carcinogenesis in LADs, confirming previous observations and identifying new putative pathways that should help to elucidate the biological role of LKB1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077168     DOI: 10.1038/sj.onc.1207665

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  The role of LKB1 in lung cancer.

Authors:  Montse Sanchez-Cespedes
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

2.  Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.

Authors:  Ciric To; Carol S Ringelberg; Darlene B Royce; Charlotte R Williams; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Carcinogenesis       Date:  2015-05-04       Impact factor: 4.944

Review 3.  Germline mutations predisposing to non-small cell lung cancer.

Authors:  Gerald H Clamon; Aaron D Bossler; Taher Abu Hejleh; Muhammad Furqan
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

4.  Long-Lasting Response to Nivolumab for a Patient With Lynch Syndrome-Associated Lung Adenocarcinoma.

Authors:  Keita Masuzawa; Takanori Asakura; Shinnosuke Ikemura; Hiroyuki Yasuda; Ichiro Kawada; Sosuke Takaoka; Yuichiro Hayashi; Takeshi Nakajima; Masami Arai; Koichi Fukunaga; Kenzo Soejima
Journal:  JCO Precis Oncol       Date:  2020-02-14

5.  A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma.

Authors:  Bárbara Angulo; Elena García-García; Rebeca Martínez; Ana Suárez-Gauthier; Esther Conde; Manuel Hidalgo; Fernando López-Ríos
Journal:  J Mol Diagn       Date:  2010-03-04       Impact factor: 5.568

Review 6.  LKB1, the multitasking tumour suppressor kinase.

Authors:  P A Marignani
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

7.  A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients.

Authors:  Mototsugu Matsunaga; Toshikado Kaneta; Keisuke Miwa; Wataru Ichikawa; Ken-Ichi Fujita; Fumio Nagashima; Junji Furuse; Masayoshi Kage; Yoshito Akagi; Yasutsuna Sasaki
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

8.  (Z)-1,1-Dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane induces concentration-dependent growth inhibition, apoptosis, and coordinates regulation of apoptotic genes in TRAMP cells.

Authors:  Catherine A Thomas; Stephen G Grant; Beth R Pflug; Robert H Getzenberg; Billy W Day
Journal:  Urol Oncol       Date:  2007-12-21       Impact factor: 3.498

9.  Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation.

Authors:  Wei Zhang; Junping Shi; Rentao Li; Zhiqiang Han; Ling Li; Guanghao Li; Bo Yang; Qiang Yin; Yingying Wang; Yan Ke; Qiang Li
Journal:  Oncologist       Date:  2020-02-11

Review 10.  Inherited lung cancer syndromes targeting never smokers.

Authors:  Hiromasa Yamamoto; Yasushi Yatabe; Shinichi Toyooka
Journal:  Transl Lung Cancer Res       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.